ABDOMINAL IMAGING

ORIGINAL ARTICLE



Copyright^o Author(s) - Available online at dirjournal.org. Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Magnetic resonance T1p relaxation in patients with liver fibrosis: a systematic review and meta-analysis

- Yinzhong Wang²
- Caihua Xu³
- Junqiang Lei^{1,2}

¹Lanzhou University, Department of First Clinical Medical College, Lanzhou, China

²First Hospital of Lanzhou University, Department of Radiology, Lanzhou, China

³Lanzhou University School of Basic Medical Sciences, Evidence-Based Medicine Center, Lanzhou, China

PURPOSE

This study aimed to evaluate the diagnostic performance of T1 ρ relaxation in distinguishing patients with liver fibrosis (LF) from those without.

METHODS

A systematic review was conducted using PubMed, EMBASE, Cochrane, and Web of Science databases up to February 2025 to identify studies assessing T1p for LF diagnosis.

RESULTS

Eleven studies involving 792 patients were included. T1p values were significantly higher in cirrhotic versus normal livers [weighted mean difference (WMD): 6.69, P < 0.001], and in fibrotic versus normal livers (WMD: 7.17, P = 0.006). Patients with Child–Pugh classes A, B, and C showed significantly higher T1p values compared with normal liver (P < 0.001). T1p values in LF stages F1–F3 were not significantly different from normal liver (P = 0.18), but stage F4 showed significant differences (WMD: 10.48, P = 0.02).

CONCLUSION

T1p relaxation differentiates high-grade LF from normal liver tissue.

CLINICAL SIGNIFICANCE

As a non-invasive imaging technique, $T1\rho$ shows potential for use in the diagnosis and follow-up of LF and to optimize the assessment and management of chronic liver disease.

KEYWORDS

Liver fibrosis, cirrhosis, imaging biomarker, meta-analysis, T1p relaxation

iver fibrosis (LF) progression occurs in almost all cases of chronic liver disease (CLD) and represents the most common consequence of these conditions.¹ During the healing process, excessive protein deposition in the extracellular matrix leads to scarring that connects the adjacent portal triad to the central vein, ultimately resulting in cirrhosis.²³ The main clinical manifestations of cirrhosis include impaired liver function, portal hypertension, and the development of hepatocellular carcinoma.⁴ End-stage LF is typically considered irreversible, with limited effective treatment options; however, complications of early or intermediate stages are often treatable.² Therefore, early LF detection and accurate staging are crucial for therapeutic decisions and prognosis determination.

Currently, liver biopsy serves as the gold standard for LF diagnosis, but its clinical adoption is limited due to its highly invasive nature, variability in patient and physician acceptance, risk of serious complications, and potential sampling errors. ¹⁰⁻¹² Consequently, non-invasive imaging techniques such as magnetic resonance (MR) elastography and ultrasound elastography have been developed to assess hepatic fibrosis. ¹³⁻¹⁵ However, MR elastography requires specific hardware and software, and ultrasound elastography is operator-dependent and less repro-

Corresponding author: Junqiang Lei

E-mail: leijq2011@126.com

Received 06 March 2025; revision requested 18 May 2025; last revision received 11 June 2025; accepted 28 June 2025.



Epub: 22.09.2025

Publication date: xx.xx.2025

DOI: 10.4274/dir.2025.253325

You may cite this article as: Liu X, Wang Y, Xu C, Li Y, Lei J. Magnetic resonance T1p relaxation in patients with liver fibrosis: a systematic review and meta-analysis. *Diagn Interv Radiol.* XXXX September 2025 DOI: 10.4274/dir.2025.253325 [Epub Ahead of Print].

ducible. 14-17 Therefore, there is a clear clinical need for a simpler, more objective method to non-invasively assess LF staging.

T1p refers to the spin-lattice relaxation time (ms) constant in the rotating coordinate frame, which describes the decay of transverse magnetization under a spin-locked radiofrequency field.^{18,19} As T1p is sensitive to the macromolecular components of the tissue, T1p MR imaging shows potential for evaluating LF.²⁰⁻²⁴ This meta-analysis aims to assess the diagnostic value of T1p in patients with CLD.

Methods

This systematic evaluation followed the Preferred Reporting Items for Systematic Evaluation and Meta-Analysis (PRISMA) guidelines^{25,26} and was registered with PROS-PERO (ID: CRD42024498897). Ethics approval and informed consent were not required, as systematic reviews synthesize and summarize existing literature rather than directly involving human or animal participants.

Literature search

Databases searched included PubMed, Cochrane Library, Web of Science, and Embase initially up to October 2023, using the search terms "liver" OR "hepatic" OR "hepar" AND "T1rho mapping" OR "T1rho relaxation" OR "T1p mapping" OR "T1p relaxation" (Supplementary file 1). Reference lists of all eligible studies were also screened for additional relevant publications. The search was updated in February 2025 in the same databases, and the results were screened according to the inclusion criteria.

Study selection

Eligible studies included English-language publications reporting liver T1p relaxation times and featuring at least two participant groups, one of which had cirrhosis or

Main points

- This study constitutes a pioneering advancement as the first systematic review and meta-analysis assessing the diagnostic efficacy of magnetic resonance imaging T1p relaxation for liver fibrosis (LF).
- This meta-analysis concludes that T1p can identify LF in patients with chronic liver disease, providing a new idea for non-invasive assessment of LF.
- Differences and limitations should be noted when using biomarker imaging to diagnose disease.

LF. Specific inclusion criteria were 1) patients with a definitive diagnosis of cirrhosis or hepatic fibrosis via pathological or clinical evaluation, 2) reported liver T1p values, and 3) a control group consisting of healthy individuals or patients without hepatic fibrosis. Exclusion criteria were 1) articles lacking valid data, 2) duplicate publications, 3) non-original research, and 4) non-English language literature. Two reviewers independently screened all titles and abstracts identified by the search. Articles judged eligible by at least one reviewer were retrieved as full-text manuscripts for further evaluation. Articles meeting the inclusion criteria after full-text review were included in the review. Conflicts of opinion at any stage were resolved through consensus.

Data extraction

Two investigators independently extracted the following data from the included literature: T1p relaxation times for cirrhosis and LF (combined if liver function grading or pathological stage grading was reported separately for cirrhosis), authors, year of publication, study design type, number of patients, mean age, MR imaging (MRI) hardware, pulse sequence and parameters, Child–Pugh classification²⁷ or pathological stage grading, T1p relaxation time, and standard deviation. When data were unclear or unavailable, the original authors were contacted via email. If no response was received, data were extracted from charts, if available.

Quality assessment

Two researchers evaluated the quality of the included literature using the Newcastle-Ottawa Scale (NOS)²⁶ quality assessment tool for observational studies as recommended in the Cochrane Handbook. The NOS scale includes two scales for assessing cohort and case-control study quality, covering study population selection, comparability, and exposure or outcome assessment. Each study was scored on a scale from 0 to 9. A score of ≥6 was considered indicative of high quality, whereas studies scoring ≤3 were regarded as low quality and were excluded from the analysis due to critical methodological limitations. Higher scores reflected higher study quality. Any disagreement between the two investigators was resolved through discussion, with a third researcher acting as final arbiter if necessary.

Statistical analysis

Statistical analysis was performed using Review Manager 5.4 (Cochrane), and

the results were compared using pooled estimates of weighted mean differences (WMDs) and 95% confidence intervals (CIs) for the MRI component data, with P < 0.05deemed statistically significant. Sensitivity analyses and publication bias assessments were performed using Stata 15.0 (StataCorp LLC). In calculating the combined effect sizes, we weighted all WMDs according to the sample size of the respective studies. For the T1p relaxation time, WMD was calculated as the difference between a normal liver and patients with cirrhosis or LF divided by the pooled standard deviation. The heterogeneity of the results was verified using the Q-test and I^2 statistic.²⁸ $P \ge 0.01$ and $I^2 < 50\%$ indicated low statistical heterogeneity among study results, warranting the use of a fixed-effects model for meta-analysis; conversely, higher statistical heterogeneity supported a random-effects model. Potential sources of heterogeneity (methodological, statistical, or clinical) were analyzed, with subgroup analyses conducted as appropriate. Descriptive analysis was used if the heterogeneity between groups was too large or not easily combined clinically. Positive values indicated patients with prolonged T1p relaxation times. Publication bias was assessed using Egger's test, with P > 0.1 suggesting no significant bias. The robustness of the pooled results was tested with leave-one-out sensitivity analyses: each study was sequentially excluded from the meta-analysis, and the pooled WMD and I² were recalculated. The results were considered stable if the recalculated WMD remained within the 95% CI of the overall effect estimate, and the I2 value did not fluctuate by more than 10% compared with the original value.

Results

Study selection and article screening

An initial search was conducted in October 2023 and updated in February 2025 by two researchers who each developed a search strategy. The initial search yielded 231 potentially eligible documents. After removing 99 duplicates, 132 titles and abstracts were screened, and 45 of these were excluded. After full-text review, another 76 documents were excluded (22 reviews, commentaries, or editorials; 39 animal experiments; 12 irrelevant articles; and 3 with no available data). The updated search did not identify any additional eligible publications. Ultimately, 11 articles²⁹⁻³⁹ with a total of 792 participants were included. The literature screening flowchart is shown in Figure 1.




Figure 1. The PRISMA flowchart quantifies the studies accepted and rejected within the different review stages and explains the reasons for the different review stage.

Study characteristics

The characteristics of all included studies are shown in Tables 1 and 2. T1p values were reported as outcome metrics in all 11 studies, with six assessing T1p values in patients with cirrhosis, six in patients with fibrosis, and one reporting both Child–Pugh scores and T1p values corresponding to their pathological classifications.

Quality assessment

All 11 articles included were case–control studies. Six were high-quality articles and five were medium-quality articles, as shown in Supplementary Table 1.

Descriptive analysis

Of the 11 studies, nine observed a significant increase in T1 ρ relaxation times in pa-

tients with fibrosis or cirrhosis compared with normal liver. Specifically, all six studies evaluating cirrhosis reported significantly longer T1p relaxation times, and four of the six studies assessing patients with LF reported significantly longer T1p relaxation times. Supplementary Table 2 provides the individual P values and Z-scores derived from forest plots.

Meta-analysis

Data on T1p values from patients with cirrhosis or LF were collected, and the combined WMD forest plots are shown in Figures 2 and 3, respectively. The differences between the two groups were statistically significant: cirrhosis group WMD: 6.69 [95% CI (4.14, 9.25); P < 0.001; Figure 2] and LF group WMD: 7.17 [95% CI (2.08, 12.26); P = 0.006; Figure 3].

Subgroup analysis

Two subgroup analyses were performed to assess the impact of disease severity. Statistically significant differences in T1p values were observed in patients with cirrhosis with different Child-Pugh scores when compared with controls: Child-Pugh stage A WMD 4.73 [95% CI (2.26, 7.20); P < 0.001], Child-Pugh stage B WMD 9.17 [95% CI (7.21, 11.13); P < 0.001], and Child-Pugh stage C WMD 15.97 [95% CI (9.30, 22.64); P < 0.001] (Figure 4). Comparison of T1p values of patients with different fibrosis stages showed no significant difference for stages F1-F3 [WMD: 4.38; 95% CI (-2.04, 10.80); P = 0.18]. However, stage F4 showed a significant increase [WMD: 10.48; 95% CI (1.61, 19.36); P = 0.02] (Figure 5). We also analyzed the difference in T1p values between patients with stage F1 fibrosis and healthy controls. Although the mean T1p values were higher in the F1 group, the difference was not statistically significant [WMD: 3.06, 95% CI (-1.39, 7.51); P =

Publication bias

Egger's test showed no significant publication bias for either the cirrhosis or fibrosis meta-analyses.

Sensitivity analysis

Leave-one-out sensitivity analyses showed that removing individual studies did not significantly impact the results, affirming the stability and reliability of the random-effects calculations. In addition, I² values varied by no more than 5% across all recalculated models, indicating that no single study exerted undue influence on the overall results. Detailed results are presented in Supplementary Figures 1 and 2, and the corresponding I² values are shown in Supplementary Tables 3, 4.

Table 1. Description of studies included in the systematic review								
Study	Country	Duration of patient recruitment	Age (mean/range)	Gender	Study design	Reference standard	Disease spectrum	
Chen et al.35 2018	Character 135 2010 China	2014.03-2016.11	Patient: 51 (28–75)	16 F/17 M	Prospective	Clinical	HBV, HCV, ALD	
Chen et al. ³⁵ 2018 China	Cillia	2014.03-2010.11	Control: 38 (23-64)	9 F/24 M			TIDV, TICV, ALD	
Allkemper et al. ²⁹	Germany	nv 2012.07–2013.07	Patient: 59.7 (28–74)	12 F/22 M	Prospective	Pathology	HCV, ALD, NASH, AIH, unknown	
2014	Germany	2012.07-2013.07	Control: 49 (29-76)	9 F/16 M				
Takayama et al. ³⁹ 2022	Japan	2015.10-2018.07	73.8 (22–86)	29 F/53 M	Retrospective	Pathology	HBV, HCV, ALD, NASH, AIH, glycogenosis, Non-B/C hepatitis, unknow	
Singh at al 31 2015	India	NA	Patient: 40–70	NA Duana attica		Dath alass	HCV	
Singh et al. ³¹ 2015	IIIuid	NA	Control: 27-65	NA	Prospective	Pathology	HCV	

Table 1. Continu	Table 1. Continued								
Study	Country	Duration of patient recruitment	Age (mean/range)	Gender	Study design	Reference standard	Disease spectrum		
Takayama et al. ³² 2014	Japan	2012.05-2013.07	65.2 (35–86)	18 F/35 M	Retrospective	Pathology	HBV, HCV, ALD, NAFLD, AIH, NASH, PBC, unknow		
Xie et al. ³⁴ 2017	China	2015.07-2016.03	Patient: 41.7 (21–63)	5 F/13 M	Prospective	Clinical	HBV		
Ale et al. 2017	Cillia	2013.07-2010.03	Control: 51.8 (35-74)	5F/13 M	riospective		TIDV		
Hou et al. ³⁸ 2022	China	2019.04–2019.10	58	NA	Retrospective	Pathology	NAFLD		
Suyama et al. ³⁷	Japan	2016.07-2017.01	Patient: 68 (36–87)	NA	Prospective	Clinical	HBV, HCV, AIH, NAFLD, ALD		
2021	Jupui.	2010107 2017101	Control: 30 (26-46)				,,		
Rauscher et al. ³⁰	Germany	2012.01–2012.11	Patient: 56.6 (23–80)	NA	NA	Clinical	HBV, HCV, ALD		
2014	Germany	2012.01-2012.11	Control: 42.7 (27-65)	6 F/4 M	NA .	Cillical	HDV, HCV, ALD		
Yang et al. ³³ 2016	China	2014.03–2015.11	Patient: 48.47 (34–70)	3 F/14 M	NA	Pathology			
rang et al. 2016	Cillia	2014.03-2015.11	Control: 41.44 (22–64)	19 F/21 M			HBV, HCV, ALD		
Stief 2019	Germany	2016.05-2017.03	65.2 (23–88)	129 F/84 M	Retrospective	Clinical	NA		

HBV, hepatitis B virus; HCV, hepatitis C virus; ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; AlH, autoimmune hepatitis; PBC, primary biliary cholangitis; F, female; M, male; NA, not available.

Table 2. Descripti	on of studies	included in the system	atic review					
Study	Scanner	TSL/frequency	Coil	TR/TE	Slices of T1p sequence	Shape of ROIs	Location of ROIs	Breath- control technique
Chen et al. ³⁵ 2018	3.0 T Philips	0, 10, 20, 40, 60/500	16-Ch sense XL Torso	5.1/2.55	NA	NA	Eight functionally independent segments	Respiratory- triggered 3D whole-liver coverage sequence
Allkemper et al. ²⁹ 2014	1.5T Philips	10, 20, 40, 80/500	16-Ch Torso	9.1/4.6	26	Circle	Liver parenchyma	Respiratory belt
Takayama et al. ³⁹ 2022	3.0 T Philips	0, 20, 40, 60/500	32-Ch Torso-cardiac phased-array	1.6/5.4	3	Polygonal regions	Liver parenchyma	Breath-hold
Singh et al. ³¹ 2015	1.5T Siemens	0, 10, 20, 30/500	Body and spine array	5.1/2.4	1	NA	Liver parenchyma	Breath-hold
Takayama et al. ³² 2014	3.0 T Philips	1, 20, 40, 60/500	32-Ch Torso-cardiac phased-array	2.1/0.98	3	Circle; oval	Right lobe or segment IV of the left lobe	Breath-hold
Xie et al. ³⁴ 2017	3.0 T Philips	1,10, 20, 30, 40, 50/500	16-Ch phased-array	3.8/1.82	8		Left lobes; right lobes	Breath-hold
Hou et al. ³⁸ 2022	3.0 T Philips	0, 10, 30, 50/NA	Invivo 32-Ch cardiac	2000/20	3	NA	Liver parenchyma	Breath-hold
Suyama et al. ³⁷ 2021	3.0 T Philips	0, 10, 20, 40, 60/1000	32-Ch torso	4.3/2.2	11	Focal	Right lobe	Breath-hold
Rauscher et al. ³⁰ 2014	1.5T Siemens	4, 8, 16, 32, 48/NA	body and spine matrix	3/1.31	1	Circle/irregular	Right lobe	Breath-hold
Yang et al. ³³ 2016	3.0 T Philips	1, 27, 54/500	16-Ch sense XL torso	2.1/1.02	3	Oval	NA	Breath-hold
Stief et al. ³⁶ 2019	1.5T Siemens	0, 10, 20, 30, 40, 50/500	One-Ch body coil and 8-Ch surface coils	5.1/2.4	2	Circle	Right lobe	NA
TSL, time of spin-lock;	ΓR, repetition time	e; TE, echo time; Ch, channel; F	ROI, region of interest; NA,	not available	2.			

	Cirrhosis Healthy			Mean Difference		Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Allkemper 2014	49.81	2.9	32	40.9	2.9	25	18.6%	8.91 [7.39, 10.43]	-
Chen 2018	48.69	4.78	34	39.63	3.2	33	17.9%	9.06 [7.12, 11.00]	
Rauscher 2014	57.4	7.4	21	47.8	4.2	10	13.2%	9.60 [5.50, 13.70]	
Stief 2019	51.11	3.45	47	47.56	4.17	166	19.1%	3.55 [2.38, 4.72]	
Takayama 2022	55.66	6.47	82	51.7	6.3	21	15.6%	3.96 [0.92, 7.00]	
Yang 2016	55.58	5.76	17	50.13	3.88	34	15.6%	5.45 [2.42, 8.48]	
Total (95% CI)			233			289	100.0%	6.69 [4.14, 9.25]	•
Heterogeneity: Tau2=	Heterogeneity: Tau ² = 8.53; Chi ² = 45.14, df = 5 (P < 0.00001); I ² = 89%								-10 -5 0 5 10
Test for overall effect:	Z = 5.13	(P < (0.00001	1)					Favours [Cirrhosis] Favours [Healthy]

Figure 2. Forest plot showing individual differences and pooled mean standard deviation of T1p relaxation times (ms) in healthy controls and patients with cirrhosis. CI, confidence interval; SD, standard deviation; IV, inverse variance.




Figure 3. Forest plot showing individual differences and pooled mean standard deviation of T1ρ relaxation times (ms) for healthy controls and patients with fibrosis. CI, confidence interval; SD, standard deviation; IV, inverse variance.

	Čin	rhosis	:	He	althy	,		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.2.1 CPA									
Allkemper 2014	45.4	1.6	11	40.9	2.9	25	40.5%	4.50 [3.02, 5.98]	-
Chen 2018	46.9	5.2	21	39.63	3.2	33	32.1%	7.27 [4.79, 9.75]	-
Takayama 2022	53.8	6.1	69	51.7	6.3	21	27.4%	2.10 [-0.95, 5.15]	 • -
Subtotal (95% CI)			101			79	100.0%	4.73 [2.26, 7.20]	•
Heterogeneity: Tau2:	= 3.34; Ch	ni² = 6.	97, df:	= 2 (P =	0.03	$ 1^2 = 71 $	1%		
Test for overall effect	Z = 3.76	(P = 0	0.0002)						
1.2.2 CPB									_
Allkemper 2014	50	3	12	40.9	2.9	25	92.3%	9.10 [7.06, 11.14]	-
Takayama 2022	61.7	9.4	8	51.7	6.3	21	7.7%	10.00 [2.95, 17.05]	
Subtotal (95% CI)			20			46	100.0%	9.17 [7.21, 11.13]	•
Heterogeneity: Tau2:	= 0.00; Ch	ni²= 0.	.06, df:	= 1 (P =	0.81)	$; I^2 = 0.9$	%		
Test for overall effect	Z=9.16	(P < 0	.00001	1)					
1.2.3 CPC									
Allkemper 2014	54	3.7	11	40.9	2.9	25	58.4%	13.10 [10.64, 15.56]	
Takayama 2022	71.7	6.2	5	51.7	6.3	21	41.6%	20.00 [13.93, 26.07]	
Subtotal (95% CI)			16			46	100.0%	15.97 [9.30, 22.64]	
Heterogeneity: Tau2:	= 18.23; 0	chi²=	4.27, di	f=1 (P:	= 0.0	4); $1^2 = 7$	77%		
Test for overall effect	Z = 4.70	(P < 0	0.00001	1)					
1.2.4 CPB+CPC									_
Chen 2018	52.12	3.81	11	39.63	3.2	33	100.0%	12.49 [9.99, 14.99]	-
Subtotal (95% CI)			11			33	100.0%	12.49 [9.99, 14.99]	•
Heterogeneity: Not a	pplicable								
Test for overall effect	Z=9.78	(P < 0	0.00001	1)					
									-20 -10 0 10 20
									Favours (experimental) Favours (control)
Test for subaroup di	fferences	: Chi²:	= 23.20). df = 3	(P <	0.00011	1 = 87.1	%	ravours (experimental) Favours (control)

Figure 4. Forest plots showing individual differences in T1p relaxation times (ms) and pooled mean standard deviations for healthy controls and patients with cirrhosis with different Child–Pugh scores. SD, standard deviation; CI, confidence interval; CPA, Child–Pugh A; CPB, Child–Pugh B; CPC, Child–Pugh C; IV, inverse variance




Figure 5. Forest plots showing individual differences in T1p relaxation times (ms) and pooled mean standard deviations for healthy controls and patients with different degrees of liver fibrosis. CI, confidence interval; IV, inverse variance; SD, standard deviation.

Discussion

Cirrhosis represents the advanced stage of various CLDs, and several imaging techniques facilitate direct diagnosis and staging of LF, including state or shear wave elastography, perfusion or dual-energy computed tomography. liver-specific contrast-enhanced MRI, diffusion-weighted MRI, and MR elastography.40-45 T1p imaging, an emerging imaging technique, is currently used to detect macromolecular levels, and its diagnosis of LF may depend on the overall loss of macromolecule content and an increase in water fraction.46 Our study, based on data from 11 studies involving 792 participants, showed that T1p relaxation time was effective in differentiating between normal livers and patients with LF. These findings align with previous animal studies⁴⁷⁻⁵⁰ and underscore the potential of T1p values in reflecting the severity of LF.

The results of the subgroup analyses further indicated that T1p relaxation times showed a significant advantage in differentiating between varying degrees of cirrhosis as the disease progressed. Specifically, there was a significant difference between T1p values for cirrhosis across Child-Pugh stages compared with normal liver, and this difference increased with higher Child-Pugh scores. Furthermore, in the comparison of different fibrosis stages, although patients in stages F1-F3 did not show statistically significant differences, in stage F4 (i.e., advanced LF or cirrhosis), the difference in T1p values was statistically significant. Multiple subgrouping strategies were attempted—including by individual fibrosis stages and early (F1–2) versus advanced (F3–4) groupings—but most comparisons did not reach statistical significance due to limited data and high variability. Therefore, stages F1–3 were combined to examine overall T1p trends in early-to-moderate fibrosis.

The Child-Pugh classification for assessing liver reserve function in cirrhosis evaluates the overall functional status of the liver based on five clinical and biochemical parameters (bilirubin, albumin, coagulation time, ascites, and hepatic encephalopathy), whereas LF responds to histological alterations of the liver only. Previous studies have reported a negative correlation between T1p and liver iron concentration (LIC), suggesting that LIC may confound T1p measurements.51,52 Moreover, changes in T1p values do not always directly reflect structural changes in hepatic tissues,53,54 indicating that T1p values are sensitive to a wide range of biological and physical factors. T1p values may also be affected by unknown factors, such as inflammation, venous congestion, or lymphoedema, all of which could alter T1p signals, leading to increased differences in T1p signals in various regions of the liver, thus affecting fibrosis assessment. In addition, comorbidities such as diabetes and obesity may also interfere with the interpretation of the T1o signal. further increasing the variability of the signal. Therefore, more studies are needed to understand the effect of LF on liver T1p values.

One strength of this study is that it is the first meta-analysis of the effectiveness of T1p in differentiating normal liver from CLD-related fibrosis, conducted in accordance with established guidelines for systematic reviews and meta-analyses.²⁵ This included consensus among multiple reviewers at each step of the literature search, study selection, and data extraction; quality assessment of the studies; publication bias assessment and adjustment; and preplanned meta-analyses, including sensitivity analyses based on a priori assumptions in the event of substantial heterogeneity. However, the analysis encountered high heterogeneity among the included studies (>50% for the primary outcome), with the source of this heterogeneity remaining unidentified despite subgroup analyses. Moreover, the limited number of T1p studies on LF and small sample sizes further emphasize the need for additional research to strengthen confidence in the results.

Considerable variation was noted between MRI methods in the included studies, including scanners, coils, software, and pulse sequences, all of which can affect T1p relaxation. In this review alone, two brands of scanners, two magnet strengths, and seven different coils were identified (Table 2). Choice of pulse sequence can also significantly affect relaxation time, with a difference of as much as 10 ms observed across commonly used sequences. 55,56 Post-processing and segmentation can also affect T1p values, such as how the assessor defines the region of interest (ROI), dif-

ferences in the ROI between studies, the number of slices included in the ROI,⁵⁷ the proximity of the border to other tissues, and partial volume effects.⁵⁸ Continued use of the recommended standardized terminology and ROI definitions will improve the comparability of ROIs across studies and study sites.⁵⁹ This study identified substantial differences in methods across testing sites, suggesting that considerable caution should be adopted when making comparisons across studies and highlighting the limitations in the current state of T1p relaxation as an imaging biomarker.

Improving the reliability of compositional MRI as an imaging biomarker requires comparability across scanners and research institutions. The results of this study support current international efforts by researchers and vendors to improve sequencing, calibration, and standardization,60 for example, the use of a calibration phantom to develop calibration functions to account for the different hardware and software used in different institutions. 60,61 Meanwhile, the findings from this study suggest that the future use of MRI component measurements as potential biomarkers would benefit from a deeper understanding of the impact of different testing methods and more standardization of data collection and analysis methods. 62,63

Although this study provides a systematic analysis of the effectiveness of hepatic fibrosis detection with T1p by integrating the existing literature, there are still some limitations. First, the small number of original studies included limits our ability to draw more generalizable conclusions. Second, the different studies involved different groups of patients who varied in disease severity, LF etiology, age, and gender ratio, which may have affected T1p performance and thus the generalizability of the results. Third, the imaging parameters used in different studies (different settings of the T1p imaging sequence, different models of imaging equipment, different breathing control techniques, location of the ROIs, etc.) may have also contributed to the heterogeneity of the results.

The significant heterogeneity observed in the combined effect size of T1p relaxation times underscores the need for further investigation, particularly on the impact of different CLD stages. Subgroup analyses hint at vary-

ing degrees of heterogeneity across LF stages, suggesting the need for standardized assessment criteria and additional prospective studies to minimize bias and validate the diagnostic utility of T1p for LF staging. Although T1p values exhibited slight differences across fibrosis stages, they demonstrated limited ability to differentiate early-stage fibrosis from a normal liver, yet hold promise in differentiating F4 stage fibrosis from cirrhosis. This limitation is likely due to the subtle histological changes present in early-stage fibrosis, which may be below the detection threshold of T1p mapping techniques. At stages F1-F3, collagen deposition and extracellular matrix remodeling remain relatively limited, leading to only minor alterations in tissue macromolecular content and water interaction that may not significantly affect T1p relaxation times. This observation is consistent with prior studies using MR elastography and diffusion-weighted MRI, which have also demonstrated reduced sensitivity in differentiating early-stage LF.64,65

In conclusion, based on these results, hepatic T1p relaxation measurements show great potential in identifying LF in patients with CLD. This study provides a more plausible scientific basis for the validity of T1p for detecting LF and a new idea for the non-invasive assessment of LF.

Footnotes

Conflict of interest disclosure

The authors declared no conflicts of interest

Acknowledgments

The authors thank all investigators and supporters involved in this study. This work was supported by the Health Industry Scientific Research Program of Gansu Province (GSWSKY2023-10).

References

- Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749-1761. [Crossref]
- Wallace K, Burt AD, Wright MC. Liver Fibrosis. Biochem J. 2008;411(1):1-18. [Crossref]
- Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. *Int J Mol Sci.* 2014;15(6):10578-10604. [Crossref]

- D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217-231. [Crossref]
- Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol. 2014;20(32):11033-11053.
 [Crossref]
- Friedman SL. Hepatic fibrosis -- overview. Toxicology. 2008;254(3):120-129. [Crossref]
- 7. Schuppan D, Afdhal NH. Liver cirrhosis. *Lancet*. 2008;371(9615):838-851. [Crossref]
- Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet*. 2013;381(9865):468-475. [Crossref]
- Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886-893.
- Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. *Ann Intern Med.* 1993;118(2):96-98. [Crossref]
- Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614-2618.
 [Crossref]
- Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000;32(3):477-481. [Crossref]
- Manduca A, Oliphant TE, Dresner MA, et al. Magnetic resonance elastography: noninvasive mapping of tissue elasticity. Med Image Anal. 2001;5(4):237-254. [Crossref]
- Boll DT, Merkle EM. Diffuse liver disease: strategies for hepatic CT and MR imaging. Radiographics. 2009;29(6):1591-1614.
 [Crossref]
- Yoshioka K, Hashimoto S. Can non-invasive assessment of liver fibrosis replace liver biopsy? Hepatol Res. 2012;42(3):233-240.
 [Crossref]
- Arda K, Ciledag N, Aktas E, Aribas BK, Köse K. Quantitative assessment of normal soft-tissue elasticity using shear-wave ultrasound elastography. AJR Am J Roentgenol. 2011;197(3):532-536. [Crossref]
- Yin M, Chen J, Glaser KJ, Talwalkar JA, Ehman RL. Abdominal magnetic resonance elastography. *Top Magn Reson Imaging*. 2009;20(2):79-87. [Crossref]
- Deng M, Zhao F, Yuan J, Ahuja AT, Wang YX. Liver T1p MRI measurement in healthy human subjects at 3 T: a preliminary study with a twodimensional fast-field echo sequence. Br J Radiol. 2012;85(1017):590-595. [Crossref]

- Wang YX, Yuan J, Chu ES, et al. T1rho MR imaging is sensitive to evaluate liver fibrosis: an experimental study in a rat biliary duct ligation model. *Radiology*. 2011;259(3):712-719. [Crossref]
- Duvvuri U, Goldberg AD, Kranz JK, et al. Water magnetic relaxation dispersion in biological systems: the contribution of proton exchange and implications for the noninvasive detection of cartilage degradation. *Proc Natl Acad Sci U S A*. 2001;98(22):12479-12484. [Crossref]
- Haris M, McArdle E, Fenty M, et al. Early marker for Alzheimer's disease: hippocampus T1rho (T(1rho)) estimation. *J Magn Reson Imaging*. 2009;29(5):1008-1012. [Crossref]
- Nestrasil I, Michaeli S, Liimatainen T, et al. T1rho and T2rho Mri in the evaluation of Parkinson's disease. *J Neurol*. 2010;257(6):964-968. [Crossref]
- Nguyen AM, Johannessen W, Yoder JH, et al. Noninvasive quantification of human nucleus pulposus pressure with use of T1rho-weighted magnetic resonance imaging. J Bone Joint Surg Am. 2008;90(4):796-802. [Crossref]
- Szyperski T, Luginbühl P, Otting G, Güntert P, Wüthrich K. Protein dynamics studied by rotating frame 15n spin relaxation times. J Biomol NMR. 1993;3(2):151-164. [Crossref]
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. [Crossref]
- Wells GA, Wells G, Shea B, et al. The Newcastle-Ottawa Scale (Nos) for assessing the quality of nonrandomised studies in meta-analyses. 2014. [Crossref]
- de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743-752. [Crossref]
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. [Crossref]
- Allkemper T, Sagmeister F, Cicinnati V, et al. Evaluation of fibrotic liver disease with wholeliver T1r MR imaging: a feasibility study at 1.5 T. Radiology. 2014;271(2):408-415. [Crossref]
- Rauscher I, Eiber M, Ganter C, et al. Evaluation of T1p as a potential MR biomarker for liver cirrhosis: comparison of healthy control subjects and patients with liver cirrhosis. Eur J Radiol. 2014;83(6):900-904. [Crossref]
- Singh A, Reddy D, Haris M, et al. T1p MRI of healthy and fibrotic human livers at 1.5 T. J Transl Med. 2015;13:292. [Crossref]
- Takayama Y, Nishie A, Asayama Y, et al. T1 P relaxation of the liver: a potential biomarker of liver function. *J Magn Reson Imaging*. 2015;42(1):188-195. [Crossref]
- 33. Yang Q, Yu T, Yun S, et al. Comparison of multislice breath-hold and 3d respiratory

- triggered T1 P imaging of liver in healthy volunteers and liver cirrhosis patients in 3.0 T MRI. *J Magn Reson Imaging*. 2016;44(4):906-913. [Crossref]
- 34. Xie S, Li Q, Cheng Y, et al. Impact of liver fibrosis and fatty liver on t1rho measurements: a prospective study. *Korean J Radiol*. 2017;18(6):898-905. [Crossref]
- Chen W, Chen X, Yang L, et al. Quantitative assessment of liver function with whole-liver T1rho mapping at 3.0t. Magn Reson Imaging. 2018;46:75-80. [Crossref]
- 36. Stief JD, Haase M, Lüdemann L, et al. Combined morphological and functional liver MRI using spin-lattice relaxation in the rotating frame (T1p) in conjunction with gadoxetic acid-enhanced MRI. *Sci Rep.* 2019;9:2083. [Crossref]
- Suyama Y, Tomita K, Soga S, et al. T1p magnetic resonance imaging value as a potential marker to assess the severity of liver fibrosis: a pilot study. Eur J Radiol Open. 2021;8:100321. [Crossref]
- Hou J, Wong VW, Qian Y, et al. Detecting earlystage liver fibrosis using macromolecular proton fraction mapping based on spin-lock MRI: preliminary observations. J Magn Reson Imaging. 2023;57(2):485-492. [Crossref]
- 39. Takayama Y, Nishie A, Ishimatsu K, et al. Diagnostic Potential of T1p and T2 relaxations in assessing the severity of liver fibrosis and necro-inflammation. *Magn Reson Imaging*. 2022;87:104-112. [Crossref]
- Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a metaanalysis of diagnostic accuracy. *J Hepatol*. 2011;54(4):650-659. [Crossref]
- 41. Ronot M, Asselah T, Paradis V, et al. Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. *Radiology*. 2010;256(1):135-142. [Crossref]
- Wang L, Fan J, Ding X, Sun J, Zhang M. Assessment of liver fibrosis in the early stages with perfusion CT. Int J Clin Exp Med. 2015;8(9):15276-15282. [Crossref]
- 43. Ding Y, Rao S, Yang L, Chen C, Zeng M. Comparison of the effect of region-of-interest methods using gadoxetic acid-enhanced MR imaging with diffusion-weighted imaging on staging hepatic fibrosis. *Radiol Med*. 2016;121(11):821-827. [Crossref]
- 44. Watanabe H, Kanematsu M, Goshima S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations. *Radiology*. 2011;259(1):142-150. [Crossref]
- Venkatesh SK, Wang G, Lim SG, Wee A. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol. 2014;24(1):70-78. [Crossref]

- Wang P, Zhu H, Kang H, Gore JC. R_{1p} dispersion and sodium imaging in human calf muscle. Magn Reson Imaging. 2017;42:139-143.
 [Crossref]
- 47. Koon CM, Zhang X, Chen W, Chu ES, San Lau CB, Wáng YX. Black blood T1rho MR imaging may diagnose early stage liver fibrosis: a proof-of-principle study with rat biliary duct ligation model. Quant Imaging Med Surg. 2016;6(4):353-363. [Crossref]
- 48. Hu G, Zhang X, Liang W, et al. Assessment of liver fibrosis in rats by MRI with apparent diffusion coefficient and T1 relaxation time in the rotating frame. *J Magn Reson Imaging*. 2016;43(5):1082-1089. [Crossref]
- Li J, Lai B, Zhang F, Liang B, Yang Q. Value of T1rho in Quantitative Diagnosis of Liver Fibrosis in Rats. Chinese Journal of Medical Imaging Technology. 2019;35(10):1445-1449.
 [Crossref]
- Lu Y, Wang Q, Zhang T, et al. Staging liver fibrosis: comparison of native T1 mapping, T2 mapping, and T1p: an experimental study in rats with bile duct ligation and carbon tetrachloride at 11.7 T MRI. J Magn Reson Imaging. 2022;55(2):507-517. [Crossref]
- 51. Wáng YXJ, Chen W, Deng M. How liver pathologies contribute to T1rho contrast require more careful studies. *Quant Imaging Med Surg.* 2017;7(5):608-613. [Crossref]
- Qian Y, Hou J, Jiang B, et al. Characterization and correction of the effects of hepatic iron on T_{1p} relaxation in the liver at 3.0T. *Magn Reson Med*. 2022;88(4):1828-1839. [Crossref]
- Zhao F, Wang YX, Yuan J, et al. Mr T1p as an imaging biomarker for monitoring liver injury progression and regression: an experimental study in rats with carbon tetrachloride intoxication. Eur Radiol. 2012;22(8):1709-1716.

 [Crossref]
- 54. Gilani IA, Sepponen R. Quantitative rotating frame relaxometry methods in MRI. *NMR Biomed*. 2016;29(6):841-861. [Crossref]
- Eckstein F, Cicuttini F, Raynauld JP, Waterton JC, Peterfy C. Magnetic resonance imaging (MRI) of articular cartilage in knee osteoarthritis (OA): morphological assessment. Osteoarthritis Cartilage. 2006;14(Suppl A):46-75. [Crossref]
- Pai A, Li X, Majumdar S. A comparative study at 3 T of sequence dependence of T2 quantitation in the knee. *Magn Reson Imaging*. 2008;26(9):1215-1220. [Crossref]
- Crawley AP, Henkelman RM. Errors in T2 estimation using multislice multiple-echo imaging. Magn Reson Med. 1987;4(1):34-47.
 [Crossref]
- 58. Eckstein F, Heudorfer L, Faber SC, Burgkart R, Englmeier KH, Reiser M. Long-term and resegmentation precision of quantitative
 - cartilage MR imaging (qMRI). *Osteoarthritis Cartilage*. 2002;10(12):922-928. [Crossref]

- Eckstein F, Ateshian G, Burgkart R, et al. Proposal for a nomenclature for magnetic resonance imaging based measu res of articular cartilage in osteoarthritis. Osteoarthritis Cartilage. 2006;14(10):974-983.
 [Crossref]
- 60. Link TM, Li X. Establishing compositional MRI of cartilage as a biomarker for clinical practice. *Osteoarthritis Cartilage*. 2018;26(9):1137-1139. [Crossref]
- 61. Keenan KE, Ainslie M, Barker AJ, et al. Quantitative magnetic resonance imaging phantoms: a review and the need for a system


Supplementary File 1. The following is an example of the full search strategy used for PubMed.

- 1. T1rho*
- 2. T1ρ*


- phantom. *Magn Reson Med*. 2017;79(1):48-61. [Crossref]
- 62. Li X, Pedoia V, Kumar D, et al. Cartilage T1p and T2 relaxation times: longitudinal reproducibility and variations using different coils, MR systems and sites. *Osteoarthritis Cartilage*. 2015;23(12):2214-2223. [Crossref]
- 63. Roemer F, Kijowski R, Guermazi A. Editorial: from theory to practice the challenges of compositional MRI in osteoarthritis research.

 Osteoarthritis Cartilage. 2017;25(12):1923-1925. [Crossref]
- 64. Huwart L, Peeters F, Sinkus R, et al. Liver fibrosis: non-invasive assessment with MR elastography. *NMR Biomed*. 2006;19(2):173-179. [Crossref]
- 65. Taouli B, Tolia AJ, Losada M, et al. Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. *AJR Am J Roentgenol*. 2007;189(4):799-806. [Crossref]
- T1rho relaxation time* OR T1p relaxation time*
- 4. T1ρ mapping* OR T1rho mapping*
- 5. 1 OR 2 OR 3 OR 4
- 6. Liver*

- 7. Hepar*
- 8. Hepatic*
- 9. 6 OR 7 OR 8
- 10. 9 AND 5



Supplementary Figure 1. Sensitivity analysis of cirrhotic patients and normal liver. CI, confidence interval.



Supplementary Figure 2. Sensitivity analysis of fibrosis patients and normal liver. CI, confidence interval.

Supplementary Table 1. Inclusion of case-control studies NOS score (points)							
Study	Selection	Comparability	Exposure	Quality scores			
Chen et al. ³⁵ 2018	3	0	2	6			
Allkemper et al. ²⁹ 2014	4	1	2	7			
Takayama et al. ³⁹ 2022	4	0	2	6			
Singh et al. ³¹ 2015	3	1	2	6			
Takayama et al. ³² 2014	4	1	2	7			
Xie et al. ³⁴ 2017	4	1	2	7			
Hou et al. ³⁸ 2022	4	1	2	7			
Suyama et al. ³⁷ 2021	4	0	2	6			
Rauscher et al. ³⁰ 2014	4	1	2	7			
Yang et al. ³³ 2016	4	1	2	7			
Stief et al. ³⁶ 2019	3	0	2	5			
NOS, Newcastle-Ottawa scale.							

Supplementary Table 2. P values and Z-scores for individual studies included in the meta-analysis of T1 ρ relaxation times							
Study	Mean difference	95% CI lower	95% Cl upper	Z-score	P value		
Chen et al.35 2018	9.06	7.12	11.0	9.15	<0.0001		
Allkemper et al. ²⁹ 2014	8.91	7.39	10.43	11.49	<0.0001		
Rauscher et al. ³⁰ 2014	9.6	5.5	13.7	4.59	<0.0001		
Stief et al. ³⁶ 2019	3.55	2.38	4.72	5.95	<0.0001		
Takayama et al. ³⁹ 2022 (cirrhosis)	3.96	0.92	7.0	2.55	0.0107		
Yang et al. ³¹ 2016	5.45	2.42	8.48	3.53	0.0004		
Hou et al. ³⁸ 2022	-0.61	-2.38	1.16	-0.68	0.4994		
Singh et al. ³¹ 2015	13.41	9.72	17.1	7.12	<0.0001		
Suyama et al. ³⁷ 2021	21.1	12.93	29.27	5.06	<0.0001		
Takayama et al. ³² 2014	0.53	-2.37	3.43	0.36	0.72		
Takayama et al. ³⁹ 2022 (fibrosis)	5.34	2.22	8.46	3.34	0.0008		
Xie et al. ³⁴ 2017	7.7	4.3	11.1	4.44	<0.0001		
CI, confidence interval.							

Supplementary Table 3. Leave-one-out sensitivity analysis of heterogeneity (I²)						
Study	l² after removal (%)	Δ I ²	Stable			
Chen et al. ³⁵ 2018	0.92	0	Yes			
Allkemper et al. ²⁹ 2014	0.91	0.01	Yes			
Rauscher et al. ³⁰ 2014	0.93	0	Yes			
Stief et al. ³⁶ 2019	0.92	0	Yes			
Takayama et al. ³⁹ 2022 (cirrhosis)	0.93	0.01	Yes			
Yang et al. ³³ 2016	0.93	0.01	Yes			
Hou et al. ³⁸ 2022	0.89	0.03	Yes			
Singh et al. ³¹ 2015	0.92	0	Yes			
Suyama et al. ³⁷ 2021	0.92	0	Yes			
Takayama et al. ³² 2014	0.92	0	Yes			
Takayama et al. ³⁹ (fibrosis)	0.93	0.01	Yes			
Xie et al. ³⁴ 2017	0.93	0.01	Yes			

				_	
Study	Mean difference	95% CI lower	95% Cl upper	Z-score	P value
Chen et al. ³⁵ 2018	9.06	7.12	11.0	9.15	<0.0001
Allkemper et al. 29 2014	8.91	7.39	10.43	11.49	<0.0001
Rauscher et al. ³⁰ 2014	9.6	5.5	13.7	4.59	<0.0001
Stief et al. ³⁶ 2019	3.55	2.38	4.72	5.95	<0.0001
Takayama et al. ³⁹ 2022 (cirrhosis)	3.96	0.92	7.0	2.55	0.0107
Yang et al.³³ 2016	5.45	2.42	8.48	3.53	0.0004
Hou et al. ³⁸ 2022	-0.61	-2.38	1.16	-0.68	0.4994
Singh et al. ³¹ 2015	13.41	9.72	17.1	7.12	<0.0001
Suyama et al. ³⁷ 2021	21.1	12.93	29.27	5.06	<0.0001
Takayama et al. ³² 2014	0.53	-2.37	3.43	0.36	0.72
Takayama et al. ³⁹ (fibrosis)	5.34	2.22	8.46	3.34	0.0008
Xie et al. ³⁴ 2017	7.7	4.3	11.1	4.44	<0.0001